Photos: Here's why Sun Pharma is doling out billions to buy troubled rival Ranbaxy

Sun, a top player in the Indian pharma industry, has acquired several companies in the past but of a relatively-smaller nature, the previous most-high profile acquisition being of Israeli drugmaker Taro.

[caption id=“attachment_81355” align=“aligncenter” width=“860”] In a mega $4 billion deal, Sun Pharma is buying troubled Indian peer Ranbaxy in an all-stock deal. However, Sun is paying is paying less than what Japan’s Daiichi had paid when it acquired Ranbaxy in 2008 from its erstwhire promoters Malvinder and Shivinder Singh for $4.6 billion. Source: Sun Pharma’s investor presentation[/caption]